Role of VHL gene mutation in human renal cell carcinoma

Tumor Biology

Volumn 33, Issue 1, 2012, Pages 9-16

  Arjumand, Wani ^a   Sultana, Sarwat ^a  

^a HAMDARD UNIVERSITY   (India)

Author keywords

Hypoxia response elements; Hypoxia inducible factor; Renal cell carcinoma; Vascular endothelial growth factor; Von Hippel Lindau

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MESSENGER RNA; VON HIPPEL LINDAU PROTEIN;

ANGIOMA; CENTRAL NERVOUS SYSTEM TUMOR; DISEASE ASSOCIATION; EAR TUMOR; ENDOLYMPHATIC SAC; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HEMANGIOBLASTOMA; HUMAN; KIDNEY CARCINOMA; MUTATIONAL ANALYSIS; MUTATOR GENE; PANCREAS CYST; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; RETINA TUMOR; REVIEW; UBIQUITINATION; VON HIPPEL LINDAU DISEASE; VON HIPPEL LINDAU GENE;

EID: 83655196994     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-011-0257-3     Document Type: Review

References (66)

1. MK Kashyap A Kumar N Emelianenko A Kashyap R Kaushik R Huang M Khullar SK Sharma SK Singh AK Bhargave 2005 Biochemical and molecular markers in renal cell carcinoma: an update and future prospects Biomarkers 10 258 94 16191485 10.1080/13547500500218534 1:CAS:528:DC%2BD2MXhtV2htLbJ (Pubitemid 41448389)
2. A Mancuso CN Sternberg 2005 New treatments for metastatic kidney cancer Can J Urol 12 66 15780170
3. B Ljungberg SC Campbell HY Cho D Jacqmin JE Lee S Weikert LA Kiemeney 2011 The epidemiology of renal cell carcinoma Eur Urol 60 4 e29 e36 10.1016/j.eururo.2011.06.049
4. Lawrence TS, Ten Haken RK, Giaccia A. Principles of radiation oncology. Cancer: principles and practice of oncology. 8th ed. Philadelphia: Williams and Wilkins; 2008.
5. A Jemal R Siegel J Xu E Ward 2010 Cancer statistics, 2010 CA Cancer J Clin 60 5 277 300 20610543 10.3322/caac.20073
6. L Lipworth RE Tarone JK McLaughlin 2006 The epidemiology of renal cell carcinoma J Urol 176 2353 8 17085101 10.1016/j.juro.2006.07.130 (Pubitemid 44665976)
7. M Malvezzi A Arfé P Bertuccio F Levi C La Vecchia E Negri 2011 European cancer mortality predictions for the year 2011 Ann Oncol 22 947 21303801 10.1093/annonc/mdq774 1:STN:280:DC%2BC3MzltV2huw%3D%3D
8. Ferlay J, Shin HR, Bray F, Parkin DM. Globocan 2008 v1. 2, cancer incidence and mortality worldwide: IARC CancerBase no. 10 (internet). International Agency for Research on Cancer, Lyon, France, 2010.
9. CS Hollenbeak LE Nikkel EW Schaefer E Alemao N Ghahramani JD Raman 2011 Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma J Manag Care Pharm 17 610 21942302
10. BD Humphreys 2011 Genetic tracing of the epithelial lineage during mammalian kidney repair Kidney Int Suppl 1 83 6 10.1038/kisup.2011.19
11. D Bodmer W Van Den Hurk JJM van Groningen MJ Eleveld GJM Martens MAJ Weterman A Geurts van Kessel 2002 Understanding familial and non-familial renal cell cancer Hum Mol Genet 11 2489 12351585 10.1093/hmg/11.20.2489 1:CAS:528:DC%2BD38XnvVenurw%3D
12. WH Chow LM Dong SS Devesa 2010 Epidemiology and risk factors for kidney cancer Nat Rev Urol 7 245 20448658 10.1038/nrurol.2010.46
13. LD Nagaprashantha R Vatsyayan J Singhal P Lelsani L Prokai S Awasthi SS Singhal 2011 2-Hydroxyflavanone inhibits proliferation, tumor vascularization and promotes normal differentiation in VHL-mutant renal cell carcinoma Carcinogenesis 32 568 21304051 10.1093/carcin/bgr021 1:CAS:528: DC%2BC3MXkt1Giu74%3D
14. CL Cowey WK Rathmell 2008 Using molecular biology to develop drugs renal cell carcinoma Expert Opin Drug Discov 3 311 27 20648240 10.1517/17460441.3.3. 311 1:CAS:528:DC%2BD1cXks1Ciurs%3D (Pubitemid 351425375)
15. WG Kaelin 2007 The Von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma Clin Cancer Res 13 680s 17255293 10.1158/1078-0432.CCR-06- 1865 1:CAS:528:DC%2BD2sXoslSrug%3D%3D
16. RJ Motzer TE Hutson P Tomczak MD Michaelson RM Bukowski O Rixe S Oudard S Negrier C Szczylik ST Kim 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Eng J Med 356 115 10.1056/NEJMoa065044 1:CAS:528:DC%2BD2sXksVGqsw%3D%3D (Pubitemid 46089672)
17. B Escudier T Eisen WM Stadler C Szczylik S Oudard M Siebels S Negrier C Chevreau E Solska AA Desai 2007 Sorafenib in advanced clear-cell renal-cell carcinoma N Eng J Med 356 125 10.1056/NEJMoa060655 1:CAS:528: DC%2BD2sXksVKitg%3D%3D (Pubitemid 46089673)
18. G Hudes M Carducci P Tomczak J Dutcher R Figlin A Kapoor E Staroslawska J Sosman D McDermott I Bodrogi 2007 Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2271 81 17538086 10.1056/NEJMoa066838 1:CAS:528:DC%2BD2sXmtVKkurs%3D (Pubitemid 46849157)
19. ER Maher HPH Neumann S Richard 2011 Von Hippel-Lindau disease: a clinical and scientific review Eur J Hum Genet 19 617 23 21386872 10.1038/ejhg.2010.175 1:CAS:528:DC%2BC3MXmtlegsb8%3D
20. MA Maynard M Ohh 2000 Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer Am J Nephrol 24 1 13 10.1159/000075346
21. ET Collins 1894 Intra-ocular growths (two cases, brother and sister, with peculiar vascular new growth, probably retinal, affecting both eyes) Trans Ophthal Soc UK 14 141 9
22. H Ev 1904 Ueber eine sehr seltene erkrankung der nethaut Albrecht von Graef Arch Ophthalmol 59 83 106 10.1007/BF01994821
23. V Couch NM Lindor PS Karnes VV Michels 2000 Von Hippel-Lindau disease Mayo Clin 75 265 10.4065/75.3.265 1:CAS:528:DC%2BD3cXit1Wksro%3D
24. WY Kim WG Kaelin 2004 Role of VHL gene mutation in human cancer J Clin Oncol 22 4991 15611513 10.1200/JCO.2004.05.061 1:CAS:528:DC%2BD2MXptVWrsw%3D%3D (Pubitemid 46646218)
25. CL Cowey WK Rathmell 2009 VHL gene mutations in renal cell carcinoma: role as a biomarker of disease outcome and drug efficacy Curr Oncol Rep 11 94 101 19216840 10.1007/s11912-009-0015-5 1:CAS:528:DC%2BD1MXltVSluro%3D
26. A McNeill E Rattenberry R Barber P Killick F MacDonald ER Maher 2009 Genotype-phenotype correlations in vhl exon deletions Am J Med Genet A 149 2147 51
27. C Stolle G Glenn B Zbar JS Humphrey P Choyke MC Walther S Pack K Hurley C Andrey R Klausner 1998 Improved detection of germline mutations in the Von Hippel-Lindau disease tumor suppressor gene Hum Mutat 12 417 23 9829911 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K 1:CAS:528:DyaK1cXnsVyksb4%3D (Pubitemid 28512618)
28. WM Linehan G Bratslavsky PA Pinto LS Schmidt L Neckers D Bottaro R Srinivasan 2010 Molecular diagnosis and therapy of kidney cancer Annu Rev Med 61 329 20059341 10.1146/annurev.med.042808.171650 1:CAS:528:DC%2BC3cXisFylsbs%3D
29. JJ Wind RR Lonser 2011 Management of Von Hippel-Lindau disease-associated CNS lesions Expert Rev Neurother 11 1433 41 21955200 10.1586/ern.11.124
30. H Bhattacharjee H Deka S Deka MJ Barman M Mazumdar J Medhi 2010 Verteporfin photodynamic therapy of retinal capillary hemangioblastoma in Von Hippel-Lindau disease Indian J Ophthalmol 58 73 20029153 10.4103/0301-4738.58479
31. PR Hammel V Vilgrain B Terris A Penfornis A Sauvanet JM Correas D Chauveau 2000 Pancreatic involvement in Von Hippel-Lindau disease Gastroenterology 119 1087 95 11040195 10.1053/gast.2000.18143 1:STN:280:DC%2BD3cvptFSjsA%3D%3D
32. RN Schimke DL Collins PG Rothberg 1998 Functioning carotid paraganglioma in the Von Hippel-Lindau syndrome Am J Med Genet 80 533 4 9880225 10.1002/(SICI)1096-8628(19981228)80:5<533::AID-AJMG21>3.0.CO;2-C 1:STN:280:DyaK1M%2FpsVygtg%3D%3D (Pubitemid 29002027)
33. SF Matin K Ahrar CG Wood M Daniels E Jonasch 2008 Patterns of intervention for renal lesions in Von Hippel-Lindau disease BJU Int 102 940 5 18485044 10.1111/j.1464-410X.2008.07718.x
34. AC Young RA Craven D Cohen C Taylor C Booth P Harnden DA Cairns D Astuti W Gregory ER Maher 2009 Analysis of vhl gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma Clin Cancer Res 15 7582 19996202 10.1158/1078-0432.CCR-09-2131 1:CAS:528:DC%2BD1MXhsFGgurvM
35. K Kondo M Yao M Yoshida T Kishida T Shuin T Miura M Moriyama K Kobayashi N Sakai S Kaneko 2002 Comprehensive mutational analysis of the vhl gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters Genes Chromosome Canc 34 58 68 10.1002/gcc.10054 1:CAS:528:DC%2BD38XjtFWju7s%3D (Pubitemid 34260597)
36. JSP Yuen 2009 Molecular targeted therapy in advanced renal cell carcinoma: a review of its recent past and a glimpse into the near future Indian J Urol 25 427 19955664 10.4103/0970-1591.57899
37. M Ivan WG KaelinJr 2001 The Von Hippel-Lindau tumor suppressor protein Curr Opin Genet Dev 11 27 34 11163147 10.1016/S0959-437X(00)00152-0 1:CAS:528:DC%2BD3MXhtFSnt7s%3D (Pubitemid 32119274)
38. A Hergovich J Lisztwan R Barry P Ballschmieter W Krek 2003 Regulation of microtubule stability by the Von Hippel-Lindau tumour suppressor protein pvhl Nat Cell Biol 5 64 70 12510195 10.1038/ncb899 1:CAS:528:DC%2BD3sXivFCk (Pubitemid 36054331)
39. H Okuda S Hirai Y Takaki M Kamada M Baba N Sakai T Kishida S Kaneko M Yao S Ohno 1999 Direct interaction of the [beta]-domain of VHL tumor suppressor protein with the regulatory domain of atypical pkc isotypes Biochem Biophys Res Commun 263 491 7 10491320 10.1006/bbrc.1999.1347 1:CAS:528:DyaK1MXlvFansb0%3D (Pubitemid 29467223)
40. T Kamura MN Conrad Q Yan RC Conaway JW Conaway 1999 The rbx1 subunit of scf and VHL e3 ubiquitin ligase activates rub1 modification of cullins cdc53 and cul2 Genes Dev 13 2928 10579999 10.1101/gad.13.22.2928 1:CAS:528: DyaK1MXnvVCltLs%3D
41. I Sumara S Maerki M Peter 2008 E3 ubiquitin ligases and mitosis: embracing the complexity Trends Cell Biol 18 84 94 18215523 10.1016/j.tcb.2007. 12.001 1:CAS:528:DC%2BD1cXitVGhsbo%3D
42. ME Cockman N Masson DR Mole P Jaakkola GW Chang SC Clifford ER Maher CW Pugh PJ Ratcliffe PH Maxwell 2000 Hypoxia inducible factor- binding and ubiquitylation by the Von Hippel-Lindau tumor suppressor protein J Biol Chem 275 25733 10823831 10.1074/jbc.M002740200 1:CAS:528:DC%2BD3cXmtVeht7o%3D
43. Zbar B: VHL family alliance. Basic facts about VHL Accessed 25 Feb 2011.
44. A Pause S Lee KM Lonergan RD Klausner 1998 The Von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal Proc Natl Acad Sci 95 993 9448273 10.1073/pnas.95.3.993 1:CAS:528:DyaK1cXosFSmtw%3D%3D (Pubitemid 28124900)
45. M Ohh RL Yauch KM Lonergan JM Whaley AO Stemmer-Rachamimov DN Louis BJ Gavin N Kley WG Kaelin 1998 The Von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix Mol Cell 1 959 68 9651579 10.1016/S1097-2765(00)80096-9 1:CAS:528:DyaK1cXktlKltLw%3D (Pubitemid 128379257)
46. IJ Frew W Krek 2007 Multitasking by pVHL in tumour suppression Curr Opin Cell Biol 19 685 90 18006292 10.1016/j.ceb.2007.10.001 1:CAS:528: DC%2BD2sXhsVWisLjJ (Pubitemid 350216423)
47. JS Roe HD Youn 2006 Extra view the positive regulation of p53 by the tumor suppressor VHL Cell Cycle 5 2054 6 16969113 10.4161/cc.5.18.3247 1:CAS:528:DC%2BD28XhtlGqsr%2FJ
48. SC Clifford ME Cockman AC Smallwood DR Mole ER Woodward PH Maxwell PJ Ratcliffe ER Maher 2001 Contrasting effects on hif-1 regulation by disease-causing pVHL mutations correlate with patterns of tumourigenesis in Von Hippel-Lindau disease Hum Mol Genet 10 1029 11331613 10.1093/hmg/10.10.1029 1:CAS:528:DC%2BD3MXjslyqtLs%3D
49. MA Hoffman M Ohh H Yang JM Klco M Ivan WG Kaelin Jr 2001 Von Hippel-Lindau protein mutants linked to type 2c VHL disease preserve the ability to downregulate hif Hum Mol Genet 10 1019 11331612 10.1093/hmg/10.10.1019 1:CAS:528:DC%2BD3MXjslyqtLo%3D
50. B Lieubeau-Teillet J Rak S Jothy O Iliopoulos W Kaelin RS Kerbel 1998 Von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids Cancer Res 58 4957 9810005 1:CAS:528:DyaK1cXnt1yisLk%3D
51. EJ Davidowitz AR Schoenfeld RD Burk 2001 VHL induces renal cell differentiation and growth arrest through integration of cell-cell and cell-extracellular matrix signaling Mol Cell Biol 21 865 11154273 10.1128/MCB.21.3.865-874.2001 1:CAS:528:DC%2BD3MXmtVOkuw%3D%3D (Pubitemid 32104734)
52. NH Stickle J Chung JM Klco RP Hill WG Kaelin Jr M Ohh 2004 PVHL modification by nedd8 is required for fibronectin matrix assembly and suppression of tumor development Mol Cell Biol 24 3251 15060148 10.1128/MCB.24.8.3251-3261.2004 1:CAS:528:DC%2BD2cXjtFKjtro%3D (Pubitemid 38452070)
53. WG Kaelin Jr 2007 Von Hippel-Lindau disease Annu Rev Pathol Mech Dis 2 145 73 10.1146/annurev.pathol.2.010506.092049 1:CAS:528:DC%2BD2sXivV2isb8%3D (Pubitemid 46463864)
54. KKW To LE Huang 2005 Suppression of hypoxia-inducible factor 1 (HIF-1) transcriptional activity by the HIF prolyl hydroxylase EGLN1 J Biol Chem 280 38102 16157596 10.1074/jbc.M504342200 1:CAS:528:DC%2BD2MXhtF2is7zE (Pubitemid 41642425)
55. E Berra E Benizri A Ginouvès V Volmat D Roux J Pouysségur 2003 HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1 in normoxia EMBO J 22 4082 90 12912907 10.1093/emboj/cdg392 1:CAS:528:DC%2BD3sXmsVGgsLo%3D (Pubitemid 37021737)
56. RJ Appelhoff YM Tian RR Raval H Turley AL Harris CW Pugh PJ Ratcliffe JM Gleadle 2004 Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor J Biol Chem 279 38458 15247232 10.1074/jbc.M406026200 1:CAS:528:DC%2BD2cXnt1OqtLs%3D (Pubitemid 39295997)
57. JH Marxsen P Stengel K Doege P Heikkinen T Jokilehto T Wagner W Jelkmann P Jaakkola E Metzen 2004 Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases Biochem J 381 761 15104534 10.1042/BJ20040620 1:CAS:528:DC%2BD2cXlvFGqu7Y%3D (Pubitemid 39120486)
58. O Aprelikova GVR Chandramouli M Wood JR Vasselli J Riss JK Maranchie WM Linehan JC Barrett 2004 Regulation of HIF prolyl hydroxylases by hypoxia inducible factors J Cell Biochem 92 491 501 15156561 10.1002/jcb.20067 1:CAS:528:DC%2BD2cXkvVyhs7k%3D
59. VH Haase 2006 Hypoxia-inducible factors in the kidney Am J Physiol Renal Physiol 291 F271 16554418 10.1152/ajprenal.00071.2006 1:CAS:528: DC%2BD28XoslWqsbw%3D (Pubitemid 44148116)
60. E Kleymenova JI Everitt L Pluta M Portis JR Gnarra CL Walker 2004 Susceptibility to vascular neoplasms but no increased susceptibility to renal carcinogenesis in VHL knockout mice Carcinogenesis 25 309 14604887 10.1093/carcin/bgh017 1:CAS:528:DC%2BD2cXhslWks7s%3D (Pubitemid 38344396)
61. VH Haase JN Glickman M Socolovsky R Jaenisch 2001 Vascular tumors in livers with targeted inactivation of the Von Hippel-Lindau tumor suppressor Proc Natl Acad Sci 98 1583 11171994 10.1073/pnas.98.4.1583 1:CAS:528: DC%2BD3MXhsVWjtbc%3D (Pubitemid 32165542)
62. L Chen K Uchida A Endler F Shibasaki 2007 Mammalian tumor suppressor int6 specifically targets hypoxia inducible factor 2 for degradation by hypoxia-and pVHL-independent regulation J Biol Chem 282 12707 17324924 10.1074/jbc. M700423200 1:CAS:528:DC%2BD2sXksVSisbo%3D (Pubitemid 47100632)
63. K Kondo J Klco E Nakamura M Lechpammer WG Kaelin Jr 2002 Inhibition of HIF is necessary for tumor suppression by the Von Hippel-Lindau protein Cancer Cell 1 237 46 12086860 10.1016/S1535-6108(02)00043-0 1:CAS:528: DC%2BD38XjsFGltrY%3D (Pubitemid 41039148)
64. L Li X Lin AR Shoemaker DH Albert SW Fesik Y Shen 2006 Hypoxia-inducible factor-1 inhibition in combination with temozolomide treatment exhibits robust antitumor efficacy in vivo Clin Cancer Res 12 4747 16899626 10.1158/1078-0432. CCR-05-2842 1:CAS:528:DC%2BD28XnvVGksb4%3D (Pubitemid 44297829)
65. R Wang S Zhou S Li 2011 Cancer therapeutic agents targeting hypoxia-inducible factor-1 Curr Med Chem 18 3168 89 21671859 10.2174/092986711796391606 1:CAS:528:DC%2BC3MXpsl2rurg%3D
66. JB Brugarolas F Vazquez A Reddy WR Sellers WG Kaelin Jr 2003 TSC2 regulates VEGF through mTOR-dependent and-independent pathways Cancer Cell 4 147 58 12957289 10.1016/S1535-6108(03)00187-9 1:CAS:528:DC%2BD3sXntFegtbk%3D (Pubitemid 37045363)